JHBP (CY) HOLDINGS LIMITED (“JHBP”) was listed on the Main Board of the Hong Kong Stock Exchange on October 7, 2020 (stock code: 6998). JHBP has raised more than HK$ 2.877 billion in this Global Offering, and it is valued at more than HK$11.5 billion after the Listing (before the exercise of the over-allotment option). JHBP’s public offering in Hong Kong was 1200 times oversubscribed.
JHBP is a biotech company listed on the Hong Kong Stock Exchange pursuant to Chapter 18A of the Listing Rules. JHBP was established in December 2007, focusing on developing and commercializing oncology and autoimmune drugs. Drug candidates that JHBP has been developing encompass the top three oncology targets and five out of the ten bestselling drugs globally.
Haiwen has acted as the legal advisor as to PRC law and special consultant as to Hong Kong law of JHBP in this project. Haiwen’s mainland team and Hong Kong team have jointly provided professional legal services for JHBP on the legal issues of PRC and Hong Kong involved in the Global Offering of JHPB, and are highly regarded and recognized by our client and intermediary parties. The sponsors of this IPO are Goldman Sachs, JPMorgan Chase and Jefferies.
Haiwen has been providing full range of legal services for JHBP since 2018, including assisting JHBP in multiple rounds of financing, group restructuring, and providing professional advice and solutions for its general corporate matters.
JHBP (CY) HOLDINGS LIMITED (“JHBP”) was listed on the Main Board of the Hong Kong Stock Exchange on October 7, 2020 (stock code: 6998). JHBP has raised more than HK$ 2.877 billion in this Global Offering, and it is valued at more than HK$11.5 billion after the Listing (before the exercise of the over-allotment option). JHBP’s public offering in Hong Kong was 1200 times oversubscribed.
JHBP is a biotech company listed on the Hong Kong Stock Exchange pursuant to Chapter 18A of the Listing Rules. JHBP was established in December 2007, focusing on developing and commercializing oncology and autoimmune drugs. Drug candidates that JHBP has been developing encompass the top three oncology targets and five out of the ten bestselling drugs globally.
Haiwen has acted as the legal advisor as to PRC law and special consultant as to Hong Kong law of JHBP in this project. Haiwen’s mainland team and Hong Kong team have jointly provided professional legal services for JHBP on the legal issues of PRC and Hong Kong involved in the Global Offering of JHPB, and are highly regarded and recognized by our client and intermediary parties. The sponsors of this IPO are Goldman Sachs, JPMorgan Chase and Jefferies.
Haiwen has been providing full range of legal services for JHBP since 2018, including assisting JHBP in multiple rounds of financing, group restructuring, and providing professional advice and solutions for its general corporate matters.
Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258
近日，北京市海问律师事务所（“本所”）发现，网络上存在将一家名为“广州海问睿律咨询顾问有限公司”的主体与本所进行不当关联的大量不实信息，导致社会公众产生混淆与误解，也对本所的声誉及正常执业活动造成不良影响。
本所特此澄清，本所与“广州海问睿律咨询顾问有限公司”（成立于2025年11月）不存在任何隶属、投资、关联、合作、授权或品牌许可关系，亦从未授权任何主体以“海问”的名义提供法律咨询服务，该公司的任何行为与本所无关。
本所的官方信息、业务领域及律师团队介绍，均应以本所官方网站（www.haiwen-law.com）及官方认证的社交媒体账号（公众号名称“海问律师事务所”）发布为准。敬请广大客户、合作伙伴及社会公众通过本所官方渠道核实信息，审慎辨别，避免因信息不实而遭受损失。
对于任何侵害本所合法权益的行为，本所特此保留追究相关方法律责任的一切权利。
特此声明。
北京市海问律师事务所
2026年1月12日
